“Given a late August approval, access will need to ramp, so revenues in 2026 will be modest, with a nice ramp in 2027 and beyond.”

In context

“fy their regimen and move to one pill once a day. We will be very focused on that at launch. In addition, in the switch market—which is dynamic at about 20% switching annually as people move to the next innovation—we see opportunity for Biclen. Biktarvy will continue to remain the standard of care for many years to come with an LOE out to 2036. Some people do switch off Biktarvy and right now they are switching to competitor products. We believe Biclen gives us an opportunity to play in that switch market and capture those patients if they are going to switch anyway. Bictegravir as the integrase inhibitor standard of care and lenacapavir as a really innovative capsid inhibitor—two orthogonal mechanisms with high resistance barriers and no cross resistance—make for a very appealing option. Given a late August approval, access will need to ramp, so revenues in 2026 will be modest, with a nice ramp in 2027 and beyond. Analyst: Great, good afternoon. Thanks for taking the question. Another one on Yes2Go adherence. Joanna, I appreciate your framing of adherence as highest in the category. Is it fair to assume those comments are anchoring on aperture adherence around 50% still, and are there any reasons, based on the early days, that the greater than 80% adherence you outlined at HIV Day eighteen months ago is not still in play with the once-yearly offering? Johanna Mercier: Thanks, Carter. You are referring to adherence, not persistency, at 80%, and we still believe adherence is much greater because you are at 100% for six months. On persistency, we believe with a Q6-month regimen—and what we are seeing in early days—it is definitely stronger than what current competition is seeing. That is what is encou”